Kashif Rashid was named Chief Legal Officer of Sight Sciences, Inc., effective August 10, 2026. As of November 6, 2026, Sight Sciences, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on August 10, 2026, naming 1 appointment (Form 8-K, August 10, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Sight Sciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Sight Sciences, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-08-10. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Sight Sciences, Inc. files it.
Also on the record for Sight Sciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 8, 2026 | Stake report, Schedule 13G/A, by KCK LTD. | 2.7% of the class | 5%+ stakes | Source |
| February 4, 2026 | Stake report, Schedule 13G/A, by KCK LTD. | 7% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.01% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Sight Sciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Sight Sciences, Inc. and the records around it.
Sight Sciences, Inc. elsewhere on the record
Companies that share a holder
- KCK LTD. also filed stake reports on 1 other company: NeuroPace Inc (Sep 2025)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Sight Sciences, Inc.
Get an email when Sight Sciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Sight Sciences, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Sight Sciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sight Sciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-10 | In | Chief Legal Officer | 2026-08-10 | 8-K, 2026-08-10 |
Who leads Sight Sciences, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Legal Officer: Kashif Rashid, appointed, effective 2026-08-10 (filed 2026-08-10).
New leaders reset buying decisions — get the Full Report on Sight Sciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Legal Officer at Sight Sciences, Inc., with the record behind each one.
Find candidates like Chief Legal Officer at Sight Sciences, Inc.Every change, in the filing's words
Appointed: Kashif Rashid, Chief Legal Officer, effective 2026-08-10
On August 6, 2026, the Board of Directors (the "Board") of Sight Sciences, Inc. (the "Company") appointed Kashif Rashid to serve as the Company's Chief Legal Officer and Corporate Secretary, effective August 10, 2026.
- Mr. Rashid, aged 53, previously served as General Counsel of Nevro Corp., a medical device company dedicated to treating chronic pain, from December 2017 to January 2024, and as Senior Vice President, Corporate Development, and Chief Legal Officer from January 2024 to April 2025 (acquired by Globus Medical in April 2025).
- From March 2017 to December 2017, Mr. Rashid served as Vice President, Legal at Atara Biotherapeutics, Inc., a biotechnology company focused on T-cell immunotherapy.
- From June 2008 to February 2017, Mr. Rashid served first as Associate General Counsel and later as Deputy General Counsel at St. Jude Medical, Inc., a medical device company (acquired by Abbott in January 2017).
- From September 1998 to June 2008, Mr. Rashid served in roles of increasing responsibility at General Electric Company's Healthcare business, Loews Corporation and Kaye Scholer, LLP, a global law firm.
- Mr. Rashid received a B.S. in Business Administration from the George Washington University and a J.D. from Georgetown University Law Center.
- Employment Agreement In connection with Mr. Rashid's appointment as Chief Legal Officer and Corporate Secretary, Mr. Rashid entered into an employment agreement with the Company (the "Employment Agreement"), effective August 10, 2026.
Tools for this story
Each opens in a new tab, filled in for Sight Sciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.